PF-03187207 News
Most Popular PF-03187207 Story
Pfizer cancels NicOx drug trial in Asia
In a blow to NicOx, Pfizer decided not to launch a Phase III program for PF-03187207 in Asia. A phase II study compared PF-03187207 to Pfizer's bestselling drug Xalatan and enrolled 112 Japanese... Read more...
Latest Headlines
- August 25, 2008
Paid Research Reports
- RNA therapy: the next big thing after monoclonal antibodies?
- Biotech M&A Strategies: Deal assessments, trends and future prospects
- The Dermatology Market Outlook to 2013: Competitive landscape, pipeline analysis and growth opportunities
- Pipeline Insight: Cancer Overview - Breast, Gynecological, Genitourinary - Diverse drugs approaching the market for many tumor t
- Sales Force Effectiveness
